Engineered protein scaffolds as next-generation therapeutics
M Gebauer, A Skerra - Annual review of pharmacology and …, 2020 - annualreviews.org
The concept of engineering robust protein scaffolds for novel binding functions emerged 20
years ago, one decade after the advent of recombinant antibody technology. Early examples …
years ago, one decade after the advent of recombinant antibody technology. Early examples …
Recent advances of affibody molecules in biomedical applications
L Zhang, H Zhang - Bioorganic & Medicinal Chemistry, 2024 - Elsevier
Affibody molecules are 58-amino-acid peptides with a molecular weight of about 6.5 kDa,
derived from the Z domain of Staphylococcal Protein A. Since they have been used as …
derived from the Z domain of Staphylococcal Protein A. Since they have been used as …
Drug conjugates based on a monovalent affibody targeting vector can efficiently eradicate HER2 positive human tumors in an experimental mouse model
Simple Summary Drug conjugates, consisting of a tumor targeting part coupled to a highly
toxic molecule, are promising for treatment of many different types of cancer. However, for …
toxic molecule, are promising for treatment of many different types of cancer. However, for …
Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors
H Liu, D Jia, F Yuan, F Wang, D Wei, X Tang… - International journal of …, 2022 - Elsevier
Photothermal therapy (PTT), mediated by tumor-targeted drug delivery of indocyanine green
(ICG), is a promising strategy for cancer therapy. Human epidermal growth factor receptor 3 …
(ICG), is a promising strategy for cancer therapy. Human epidermal growth factor receptor 3 …
Affibody-drug conjugates targeting the human epidermal growth factor receptor-3 demonstrate therapeutic efficacy in mice bearing low expressing xenografts
J Zhang, SS Rinne, W Yin, CD Leitao… - ACS Pharmacology & …, 2024 - ACS Publications
The outcome of clinical trials evaluating drugs targeting the human epidermal growth factor
receptor 3 (HER3) has been poor, with primary concerns related to lack of efficacy. HER3 is …
receptor 3 (HER3) has been poor, with primary concerns related to lack of efficacy. HER3 is …
Feasibility of imaging EpCAM expression in ovarian cancer using radiolabeled DARPin Ec1
A Vorobyeva, E Konovalova, T Xu, A Schulga… - International journal of …, 2020 - mdpi.com
Epithelial cell adhesion molecule (EpCAM) is overexpressed in 55%–75% of ovarian
carcinomas (OC). EpCAM might be used as a target for a treatment of disseminated OC …
carcinomas (OC). EpCAM might be used as a target for a treatment of disseminated OC …
Engineering of TEV protease variants with redesigned substrate specificity
Due to their ability to catalytically cleave proteins and peptides, proteases present unique
opportunities for the use in industrial, biotechnological, and therapeutic applications …
opportunities for the use in industrial, biotechnological, and therapeutic applications …
Radionuclide molecular imaging of EpCAM expression in triple-negative breast cancer using the scaffold protein DARPin Ec1
A Vorobyeva, E Bezverkhniaia, E Konovalova… - Molecules, 2020 - mdpi.com
Efficient treatment of disseminated triple-negative breast cancer (TNBC) remains an unmet
clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the …
clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the …
Incorporation of a hydrophilic spacer reduces hepatic uptake of HER2-targeting affibody–DM1 drug conjugates
Affibody molecules are small affinity-engineered scaffold proteins which can be engineered
to bind to desired targets. The therapeutic potential of using an affibody molecule targeting …
to bind to desired targets. The therapeutic potential of using an affibody molecule targeting …
A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity
M Nazari, R Emamzadeh, M Jahanpanah… - International Journal of …, 2022 - Elsevier
High expression of receptor tyrosine-protein kinase erbB-3 (HER3) has been found in
several malignancies such as breast cancer. In this study, we designed, produced and …
several malignancies such as breast cancer. In this study, we designed, produced and …